Oslo, 11 June 2020: On the basis of Navamedic ASA’s (the “Company“) annual general meeting’s resolution on 3 June 2020 to authorise the board of directors of the Company (the “Board“) to issue new option shares to the executive management and other leaders in the group under the Company’s long-term incentive program, the Board has resolved to issue 480.000 new share options to the Company’s executive management.

Each option will upon exercise give the option holder the right to acquire one share in the Company. The options are granted without consideration. Pursuant to the vesting schedule and certain other terms and conditions of the grant, 1/3 of the share options will vest on the first anniversary of the day of grant, 1/3 of the share options will vest on the second anniversary of the day of grant, and the remaining 1/3 of the share options will vest on the third anniversary of the day of grant.

The exercise price of each option is NOK 19.00. Options that are not exercised within 12 months after the third anniversary of the date of grant, will subject to certain limitations, lapse without any compensation to the holder.

The following primary insiders of the Company have received options on the terms described above:

* Kathrine Gamborg Andreassen, CEO in the Company, has been granted 105.000 options. Following the grant Kathrine Gamborg Andreassen, with her related parties own 541.668 shares and 230.000 options in the Company.

* Lars Hjarrand, CFO in the Company, has been granted 75.000 options. Following the grant Lars Hjarrand, with his related parties own 185.882 shares and 150.000 options in the Company.

* Ole Henrik Eriksen, COO in the Company, has been granted 75.000 options. Following the grant Ole Henrik Eriksen, with his related parties own 491.666 shares and 75.000 options in the Company.

* Astrid T. Bratvedt, CSO in the Company, has been granted 75.000 options. Following the grant Astrid T. Bratvedt, with her related parties own 493.666 shares and 75.000 options in the Company.

* Alexander Lidmejer, Commercial Dir Specialty Pharma in the Company, has been granted 75.000 options. Following the grant Alexander Lidmejer, with his related parties own 2.400 shares and 75.000 options in the Company.

For further information please contact: Lars Hjarrand, CFO.

E-mail: lars.hjarrand@navamedic.com Phone +47 917 62 842

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.